AtriCure (NASDAQ:ATRC) Updates FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.240-0.320 for the period, compared to the consensus earnings per share estimate of 0.120. The company issued revenue guidance of $602.0 million-$610.0 million, compared to the consensus revenue estimate of $605.0 million.

AtriCure Trading Down 1.6%

ATRC traded down $0.52 on Thursday, reaching $33.00. 1,130,784 shares of the company’s stock were exchanged, compared to its average volume of 784,313. AtriCure has a twelve month low of $25.36 and a twelve month high of $43.18. The company’s 50 day moving average is $29.81 and its 200-day moving average is $31.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -330.00 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts predict that AtriCure will post 0.13 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on ATRC shares. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday. Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 4th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday. Finally, Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and an average target price of $49.12.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares of the company’s stock, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its stake in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Scotia Capital Inc. raised its holdings in shares of AtriCure by 1.2% during the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after acquiring an additional 457 shares during the period. Captrust Financial Advisors increased its holdings in AtriCure by 7.9% during the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after purchasing an additional 579 shares in the last quarter. Mackenzie Financial Corp grew its holdings in shares of AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after buying an additional 683 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in AtriCure by 1.6% in the 2nd quarter. California State Teachers Retirement System now owns 45,001 shares of the medical device company’s stock valued at $1,475,000 after buying an additional 691 shares during the last quarter. Institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.